NAME OF THE MEDICINE
Vaccine containing heat inactivated *Vibrio cholerae* O1 Inaba classic strain, formalin inactivated *Vibrio cholerae* O1 Inaba El Tor strain, heat inactivated *Vibrio cholerae* O1 Ogawa classic strain, formalin inactivated *Vibrio cholerae* O1 Ogawa classic strain, and recombinant cholera toxin B subunit.

DESCRIPTION
DUKORAL® is provided as a whitish oral liquid suspension (vaccine) in a single dose glass vial with white to off-white effervescent granules (buffer), in an accompanying sachet.

Each dose contains:

**Active ingredients**

- A total of $1.25 \times 10^{11}$ bacteria of the following strains:

  - *Vibrio cholerae* O1 Inaba classic strain, heat inactivated bacteria* ca. $31.25 \times 10^9$
  - *Vibrio cholerae* O1 Inaba El Tor strain, formalin inactivated bacteria* ca. $31.25 \times 10^9$
  - *Vibrio cholerae* O1 Ogawa classic strain, formalin inactivated bacteria* ca. $31.25 \times 10^9$
  - *Vibrio cholerae* O1 Ogawa classic strain, heat inactivated bacteria* ca. $31.25 \times 10^9$

  *bacterial count before inactivation

- Recombinant cholera toxin B subunit 1mg

**Excipients**

Vaccine, 1 dose (3mL) contains:

- Sodium phosphate, monobasic dihydrate 1.95mg
- Sodium phosphate, dibasic dihydrate 9.39mg
- Sodium chloride 25.5mg
- Water for injections to 3.0mL
Effervescent granules, one sachet (5.6g) contains:

- Sodium bicarbonate: 3600mg
- Citric acid, anhydrous: 1450mg
- Raspberry flavour: 70.0mg
- Sodium carbonate anhydrous: 400mg
- Sodium citrate: 6.0mg
- Saccharin sodium: 30.0mg

**PHARMACOLOGY**

The protection against cholera is specific for both biotype and serotype. O-antigens as well as toxin B subunit will induce immunity. Many antigenic components have been included in the vaccine in order to give a good protection. The vaccine contains no somatic or capsular antigens from O139 serogroup *Vibrio cholerae*, or from non-O1, non-O139 serogroup *Vibrio cholerae*.

Most enterotoxigenic *Escherichia coli* ETEC strains produce an enterotoxin, which is structurally, patho-physiologically and immunologically similar to cholera toxin. The heat labile enterotoxin, designated LT is neutralised by antibodies against cholera toxin subunit B.

Cholera infections are limited to the intestinal tract. Oral administration will induce local immunity.

Since the B subunit is acid labile, the vaccine is mixed with a buffering sodium hydrogen carbonate solution.

**CLINICAL TRIALS**

Clinical results have revealed a protective efficacy against cholera of 85% for the first six months in all age categories although efficacy had fallen to 52% at the end of the second year and 19% at the end of the third year. Children under the age of 2 were not examined, but protective efficacy in the 2-6-year age range was satisfactory (100%) for the first six months. In this randomised, double blind, placebo controlled study in Bangladesh, 3 doses of vaccine were given each separated by 6 weeks. Efficacy was measured 14 days after the 3rd dose. A cohort in this study received only two doses and the efficacy results were comparable with those who received three doses. The pivotal cholera efficacy studies were conducted in Bangladesh and Peru, where exposure to *Vibrio cholerae* prior to vaccination is likely to be greater than in Australia.
Table 1: Bangladesh vaccine efficacy results against cholera

<table>
<thead>
<tr>
<th>Time after vaccination</th>
<th>Vaccine n=3,721 Cholera cases</th>
<th>Placebo n=3,800 Cholera cases</th>
<th>PE, % (95% CI)</th>
<th>Vaccine n=17,420 Cholera cases</th>
<th>Placebo n=17,420 Cholera cases</th>
<th>PE, % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 months</td>
<td>0</td>
<td>9</td>
<td>100 (CI n.a.)</td>
<td>4</td>
<td>17</td>
<td>76 (30-92) p=0.009</td>
</tr>
<tr>
<td>Year 1</td>
<td>27</td>
<td>49</td>
<td>44 (10-65) p=0.016</td>
<td>20</td>
<td>82</td>
<td>76 (60-85) p&lt;0.001</td>
</tr>
<tr>
<td>Year 2</td>
<td>17</td>
<td>26</td>
<td>33 (-23-64) n.s</td>
<td>23</td>
<td>58</td>
<td>60 (36-76) p&lt;0.001</td>
</tr>
<tr>
<td>Year 3</td>
<td>23</td>
<td>18</td>
<td>&lt;0</td>
<td>18</td>
<td>33</td>
<td>45 (3-69) p=0.038</td>
</tr>
</tbody>
</table>

**INDICATIONS**
Cholera caused by serogroup O1 *Vibrio cholerae*: Active immunisation of adults and children *from two years of age*, who will be visiting areas epidemic or endemic for cholera and who are at high risk of infection.

**CONTRAINDICATIONS**
Hypersensitivity to the active substances, to any of the excipients or to formaldehyde.

Administration of DUKORAL® should be postponed for subjects suffering from acute gastrointestinal illness or acute febrile illness.

**PRECAUTIONS**
As with any vaccine, immunisation with DUKORAL® may not protect 100% of susceptible individuals. DUKORAL® confers protection specific to *Vibrio cholerae* serogroup O1. Immunisation does not protect against *V. cholerae* serogroup O139 or other species of *Vibrio cholerae*.

In cholera, the efficacy of the vaccine is against clinical disease and the vaccine does not necessarily prevent spread of cholera via a vaccinee exposed to *V. cholerae* bacteria.

Cholera vaccine is not a sole measure in prevention of cholera outbreaks. Clean hygiene practices are still required.

In subjects infected with HIV, limited data are available on immunogenicity and safety of the vaccine. Vaccine protective efficacy has not been studied in these subjects. Immunisation of HIV infected subjects could result in transient increases of viral load. DUKORAL® may not induce protective antibody levels in subjects with advanced HIV disease.

The antibody response in vaccinees with endogenous or iatrogenic immunosuppression may be insufficient.
Formaldehyde is used during the manufacturing process and trace amounts may be present in the final product. Caution should be taken in subjects with known hypersensitivity to formaldehyde.

DUKORAL® contains approximately 1.1 g sodium per dose, which should be taken into consideration by patients on a controlled sodium diet.

**Use in Children**

DUKORAL® has been given to children between 1 and 2 years of age in safety and immunogenicity studies, but the protective efficacy has not been studied in this age group. Therefore, DUKORAL® is not recommended to be used in children less than 2 years of age.

**Use in the Elderly**

There are only very limited data on protective efficacy of the vaccine in subjects aged 65 years and over.

**Carcinogenicity, Mutagenicity, Effects on Fertility**

DUKORAL® has not been evaluated for carcinogenicity, mutagenicity, or impairment of fertility.

**Use in Pregnancy – Category B2**

No animal data on reproduction toxicity are available. Following careful benefit/risk assessment the vaccine may be administered during pregnancy although no specific studies have been conducted to investigate the safety of DUKORAL® during pregnancy. However, DUKORAL® is an inactivated, non-replicating vaccine given orally and it is not taken up by the blood stream. It is therefore considered to be safe.

**Use in Lactation**

Following careful benefit/risk assessment the vaccine may be administered to lactating women. It has been given to lactating women in several studies, although no specific studies have been conducted to investigate the safety of DUKORAL® during lactation.

**Effect on Ability to Drive and Use Machines**

There is no evidence of an effect on the ability to drive and use machines.

**Effect on Laboratory Tests**

Not documented.

**INTERACTIONS WITH OTHER MEDICINES**

The vaccine is acid labile. Food and/or drink will increase acid production in the stomach and the effect of the vaccine may be impaired. Consequently, food and drink should be avoided 1 hour before and 1 hour after vaccination. Oral administration of other vaccines and medicinal products should also be avoided 1 hour before and 1 hour after administration of DUKORAL®.
Except for yellow fever vaccine, co-administration of DUKORAL® with other vaccines has not been assessed in clinical studies. The administration of an encapsulated oral typhoid vaccine and DUKORAL® should be separated by at least 8 hours.

No other vaccines/medicinal products, including oral polio vaccine and antimalarials, have been given simultaneously with DUKORAL® in clinical studies.

ADVERSE EFFECTS
Adverse reactions are adverse events that were considered to be reasonably associated with the use of DUKORAL® based on the comprehensive assessment of the available adverse event information. A causal relationship with DUKORAL® cannot be reliably established in individual cases. Further, because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect the rates observed in clinical practice.

The safety of DUKORAL® was assessed in clinical trials, including both adults and children, conducted in endemic and non-endemic countries for cholera and enterotoxigenic Escherichia coli (ETEC) producing heat-labile enterotoxin (LT). Over 94,000 doses of DUKORAL® were administered during the clinical trials. Evaluation of safety varied between trials with respect to mode of surveillance, definition of symptoms and time of follow-up. In the majority of studies adverse events were assessed by passive surveillance. The most frequently reported adverse reactions, such as gastrointestinal symptoms including abdominal pain, diarrhoea, loose stools, nausea and vomiting, occurred at similar frequencies in vaccine and placebo groups.

Frequency classification: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

Metabolism and nutrition disorder
Rare: Loss of/or poor appetite
Very rare: Dehydration

Nervous system disorders
Uncommon: Headache
Rare: Dizziness
Very rare: Drowsiness, insomnia, fainting, reduced sense of taste

Respiratory, thoracic and mediastinal disorders
Rare: Respiratory symptoms (including rhinitis and cough)

Gastrointestinal disorders
Uncommon: Diarrhoea, abdominal cramps, abdominal pain, stomach/abdominal gurgling (gas), abdominal discomfort
Rare: Vomiting, nausea
Very rare: Sore throat, dyspepsia
Skin and subcutaneous tissue disorders
Very rare: Sweating, rash

Musculoskeletal and connective tissue disorders
Very rare: Joint pain

General disorders and administration site conditions
Rare: Fever, malaise
Very rare: Fatigue, shivers

The following results were observed in a study of traveller’s diarrhoea in tourists to Morocco where participants received either vaccine or killed *E. coli K12* in sodium hydrogen carbonate buffer:

Table 2. Vaccine tolerability

<table>
<thead>
<tr>
<th>Vaccine reaction</th>
<th>Placebo N=308 (%)</th>
<th>Vaccine N=307 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Returned Vaccination forms</td>
<td>261/308 (84.7)</td>
<td>244/307 (79.5)</td>
</tr>
<tr>
<td>No symptoms</td>
<td>179 (68.6)</td>
<td>189 (77.5)</td>
</tr>
<tr>
<td>Abdominal discomfort</td>
<td>29 (11.1)</td>
<td>18 (7.4)</td>
</tr>
<tr>
<td>Loose stools</td>
<td>44 (16.9)</td>
<td>21 (8.6)</td>
</tr>
<tr>
<td>Headache</td>
<td>27 (10.3)</td>
<td>17 (7.0)</td>
</tr>
<tr>
<td>Rhinitis, cough or other respiratory symptoms</td>
<td>16 (6.1)</td>
<td>18 (7.4)</td>
</tr>
<tr>
<td>Other symptoms</td>
<td>8 (3.1)</td>
<td>11 (4.5)</td>
</tr>
</tbody>
</table>

In this study other symptoms among placebo recipients included: Oppressive feeling in diaphragm (N=1), bump below chin (N=1), itching red spots on back (N=1), intestinal gas (N=1), nausea (N=1), ache in shoulder (N=1), thirsty (N=1), nervousness (N=1). Other symptoms among vaccinees included: Nausea (N=4), fatigue (N=1), sore throat (N=1), intestinal gas (N=2), shivers (N=1), sense of fatigue (N=2).

Postmarketing data
Additional adverse reactions reported during post-marketing surveillance, are listed below. The frequency cannot be estimated from the available data.

Infections and infestations: Gastroenteritis
Blood and lymphatic system disorders: Lymphadenitis
Nervous system disorders: Paraesthesia
Vascular disorders: Hypertension
Respiratory, thoracic and mediastinal disorders: Dyspnoea, increased sputum
Gastrointestinal disorders: Flatulence
Skin and subcutaneous tissue disorders: Urticaria, angioedema, pruritus
General disorders and administration site conditions: Pain, flu-like syndrome, asthenia, chills
DOSAGE AND ADMINISTRATION

Dosage:
Primary immunisation consists of 2 doses for adults and children over the age of 6. Children from 2 to 6 years of age should receive 3 doses. Doses are to be administered at intervals of at least 1 week. If more than 6 weeks elapse between doses, the primary immunisation course should be re-started.

Booster dose: In circumstances of ongoing risk or repeated travel, a booster dose is recommended for adults after 2 years. Children from 2 to 6 years of age should receive a booster dose after 6 months.

Satisfactory protection against cholera can be expected about two weeks after completing the primary immunisation course.

No clinical data on protective efficacy of DUKORAL® against cholera after administration of booster doses are available.

Administration:
The vaccine is intended for oral use. Before ingestion, the vaccine suspension should be mixed with a buffer (sodium hydrogen carbonate) solution prepared from the supplied effervescent granules.

Dissolve the effervescent granules in approximately 150 mL of cool water to make the buffer solution. Shake the vaccine vial gently and add the contents to the buffer solution. Mix well and drink the mixture.

Children 2 to 6 years of age: half the amount of buffer solution is poured away and the remaining part (approx. 75 mL) is mixed with the entire contents of the vaccine vial.

Food and drink should be avoided for 1 hour before and 1 hour after vaccine administration.

For administration with other oral medicinal products, see ‘Interactions with other medicines’.

DUKORAL® should only be mixed with the supplied effervescent granules dissolved in water. In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

Any unused product or waste material should be disposed of in accordance with local requirements.

OVERDOSAGE
Data on overdose are limited. Adverse reactions reported following overdose have been consistent with those seen after the recommended dosing, see ‘Adverse effects’.

For information on the management of overdose, contact the Poison Information...
PRESENTATION AND STORAGE CONDITIONS

Presentation
DUKORAL® is provided as a whitish oral liquid suspension (vaccine) in a single dose glass vial with white to off-white effervescent granules (buffer), in an accompanying sachet.

The vaccine suspension is filled to a volume of 3 mL in vials (type I glass) with a rubber stopper (bromobutyl rubber) and a screw cap.

DUKORAL® is available in the following pack sizes:
- Single Dose Carton: 1 vaccine vial and 1 sachet of effervescent granules
- Two Dose Carton: 2 vaccine vials and 2 sachets of effervescent granules

Storage Conditions
Store at 2° to 8°C. REFRIGERATE. DO NOT FREEZE.
Do not use after expiry date.

NAME AND ADDRESS OF SPONSOR
CSL Limited
ABN 99 051 588 348
45 Poplar Road,
Parkville, VIC 3052
Australia

POISON SCHEDULE OF THE MEDICINE
Prescription Only Medicine (S4)

Date of first inclusion in the ARTG:
09 September 2003

Date of most recent amendment:
06 August 2015

DUKORAL® is a registered trademark of Valneva Sweden AB.